Frontlight ResearchEarly access
Taking peoplePhase 2
Letermovir to prevent cytomegalovirus after stem cell transplant from a CMV-positive donor
Tests letermovir to prevent cytomegalovirus after stem cell transplant.
Key facts
- Who runs it
- Grupo Espanol De Trasplante Hematopoyetico Y Terapia Celular
- Where
- Spain12 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Letermovir (LMV) prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients with CMV seropositive donors
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 80 people, planned
- Started
- 13 Nov 2024
- Expected to end
- 4 Nov 2027
- Type of study
- Interventional
- Record updated
- 1 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults having their first stem cell transplant from a donor. The patient has no past CMV infection, but the donor has had one. Everyone gets letermovir (LMV) to prevent CMV.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- First allogenic HCT (stem cell transplant from a donor).
- Earlier treatment
- People who already had LMV prevention treatment before joining cannot join.
- Biomarker or test result
- Before the transplant, the patient's CMV IgG blood test is negative and the donor's CMV IgG test is positive. There must be no CMV DNAemia (virus in the blood) needing antiviral treatment within 5 days before starting LMV.
Main reasons for not taking part
- Current pre-emptive treatment for CMV infection, or an earlier CMV reactivation that was not treated
- Glomerular filtration rate (GFR) </=30 mL/min/1.73m^2 (weak kidney function)
- Severe liver problems, grade 3-4 CTAE
- Allergy to LMV or to similar compounds
- Pregnancy, breastfeeding, or plans to conceive or father a child during the trial
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age ≥18 years
- First allogenic HCT
- Pre-HCT patient CMV negative IgG serology with CMV IgG positive donor serostatus
- Able to provide written consent and complete the informed consent
- Absence of CMV DNAemia requiring antiviral therapy within 5 days before initiation of LMV
Who cannot take part
- Active pre-emptive therapy for csCMV-I
- Patients who have received LMV prophylaxis prior to enrollment
- Patients with previous untreated reactivation
- History of current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or would place the subject at undue risk as judged by the investigator, such that it is not in the best interest of the subject to participate in this study
- Suspected or known hypersensitivity to active or inactive ingredients of LMV formulations
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to LMV
- Glomerular filtration rate (GFR) </=30 mL/min/1.73m^2 (equivalent to creatinine clearance (ClCr) </=10 mL/min)
- Severe hepatic function grade 3-4 CTAE at the time of study entry
- Pregnancy or breastfeeding
- Plans to conceive or father children within the projected duration of the trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To determinate the incidence of csCMV infection through week 14 post-SCT.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Letermovir (LMV) prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients with CMV seropositive donors: an exploratory study from Spanish GETH/TC Centers
- Plain-language title
- Letermovir to prevent cytomegalovirus after stem cell transplant from a CMV-positive donorGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 1 June 2026